PHARNEXT: management transactions · France · AMF

About PHARNEXT

Pharnext is a French biopharmaceutical company focused on the development of innovative drug candidates for rare and degenerative neurological diseases. Founded in Paris in 2007, the company built its scientific strategy around system biology and drug repositioning, seeking to combine well-known molecules into multi-target therapies with improved efficacy and potentially faster development timelines. Pharnext was listed in Paris in 2016 and positioned itself for years as an advanced clinical-stage biotech targeting diseases with major unmet medical needs. The company’s flagship asset is PXT3003, an oral fixed-dose combination developed for Charcot-Marie-Tooth disease type 1A (CMT1A), a rare inherited peripheral neuropathy. Pharnext advanced this program into a pivotal Phase III trial, and in May 2022 announced completion of enrollment for 387 patients in the PREMIER study. The company also reported open-label extension work and international development efforts, including regulatory and commercial ambitions in Europe, the United States, and China. These updates made PXT3003 the clear center of the company’s scientific and strategic value proposition. By 2024, however, Pharnext’s situation had deteriorated sharply. The company announced a drastic cost-cutting plan and a full review of its operating, strategic, and financial position. Euronext later indicated that trading in the shares was suspended, and public market disclosures show that a judicial liquidation proceeding was opened on August 22, 2024, with the formal announcement published at the end of August. This marks a decisive turning point in the company’s trajectory and materially changes how the market should assess its equity story. Geographically, Pharnext remained primarily anchored in France, with its headquarters in Paris, while its clinical development strategy was international from the outset. Its trials and partnering discussions extended beyond France into the broader European market, the United States, and China. From an equity-analysis perspective, Pharnext exemplifies a highly specialized small-cap biotech: narrow pipeline concentration, long development cycles, substantial funding needs, and extreme sensitivity to clinical, regulatory, and financing outcomes. Its market position was therefore less about diversified commercial revenues and more about the binary value creation potential of a single lead asset and partnering execution.